ATE465170T1 - Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten - Google Patents

Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten

Info

Publication number: ATE465170T1
Authority: AT; Austria
Prior art keywords: residue; citrulline; alanine; ornithine; lysine
Prior art date: 2000-09-05

Application number

AT01963414T

Other languages

English (en)

Inventor

Nobutaka Fujii

Original Assignee

Biokine Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-05

Filing date

2001-09-05

Publication date

2010-05-15

2001-09-05 Application filed by Biokine Therapeutics Ltd filed Critical Biokine Therapeutics Ltd

2010-05-15 Application granted granted Critical

2010-05-15 Publication of ATE465170T1 publication Critical patent/ATE465170T1/de

Links

229920001184 polypeptide Polymers 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
239000002259 anti human immunodeficiency virus agent Substances 0.000 title 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
239000004472 Lysine Substances 0.000 abstract 3
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 3
229960002173 citrulline Drugs 0.000 abstract 3
235000013477 citrulline Nutrition 0.000 abstract 3
229960003646 lysine Drugs 0.000 abstract 3
239000004475 Arginine Substances 0.000 abstract 2
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 2
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 2
229960003121 arginine Drugs 0.000 abstract 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 2
229960003104 ornithine Drugs 0.000 abstract 2
NSHFIBIUHBWAOX-SFYZADRCSA-N (2s)-1-[(2r)-2,5-diaminopentanoyl]pyrrolidine-2-carboxylic acid Chemical group NCCC[C@@H](N)C(=O)N1CCC[C@H]1C(O)=O NSHFIBIUHBWAOX-SFYZADRCSA-N 0.000 abstract 1
AIXUQKMMBQJZCU-BDAKNGLRSA-N (2s)-1-[(2r)-2,6-diaminohexanoyl]pyrrolidine-2-carboxylic acid Chemical group NCCCC[C@@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-BDAKNGLRSA-N 0.000 abstract 1
IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 abstract 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
235000004279 alanine Nutrition 0.000 abstract 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
-1 prolyl-D-ornithine Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
- Y10S530/857—Fish; fish eggs; shell fish; crustacea

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Virology (AREA)
Insects & Arthropods (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT01963414T 2000-09-05 2001-09-05 Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten ATE465170T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2000269296		2000-09-05
JP2001092306		2001-03-28
PCT/JP2001/007668 WO2002020561A1 (en)	2000-09-05	2001-09-05	Novel polypeptides and anti-hiv drugs containing the same

Publications (1)

Publication Number	Publication Date
ATE465170T1 true ATE465170T1 (de)	2010-05-15

Family

ID=26599311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01963414T ATE465170T1 (de)	2000-09-05	2001-09-05	Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten

Country Status (8)

Country	Link
US (2)	US7138488B2 (de)
EP (1)	EP1323730B1 (de)
JP (1)	JP4808363B2 (de)
AT (1)	ATE465170T1 (de)
AU (1)	AU2001284419A1 (de)
CA (1)	CA2421183C (de)
DE (1)	DE60136373D1 (de)
WO (1)	WO2002020561A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8435939B2 (en)	2000-09-05	2013-05-07	Biokine Therapeutics Ltd.	Polypeptide anti-HIV agent containing the same
AU2003261723A1 (en)	2002-08-27	2004-03-19	Takeda Chemical Industries, Ltd.	Cxcr4 antagonist and use thereof
JP4781621B2 (ja) *	2002-08-27	2011-09-28	バイオカインセラピューティックスリミテッド	Ｃｘｃｒ４拮抗薬およびその用途
WO2006126188A2 (en) *	2005-05-25	2006-11-30	Hadasit Medical Research Services And Development Ltd.	Cxcr4 antagonists for wound healing and re-epithelialization
WO2008075371A2 (en)	2006-12-21	2008-06-26	Biokine Therapeutics Ltd.	T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
BRPI1009663A2 (pt) *	2009-06-14	2016-10-11	Biokine Therapeutics Ltd	"método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
US20130303460A1 (en)	2011-01-10	2013-11-14	Biokine Therapeutics Ltd.	Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
EP2841084B1 (de)	2012-04-24	2018-05-30	Biokine Therapeutics Ltd.	Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs
JP6294459B2 (ja)	2013-03-24	2018-03-14	バイオカイン・セラピューティクス・リミテッドＢｉｏｋｉｎｅＴｈｅｒａｐｅｕｔｉｃｓＬｔｄ．	骨髄性白血病の処置方法
ES2811804T3 (es)	2013-10-31	2021-03-15	Biokine Therapeutics Ltd	Un inhibidor peptídico de CXCR4 para su uso en el tratamiento de la leucemia mieloide aguda con una mutación de FLT3
AU2015212341A1 (en)	2014-02-03	2016-09-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Use of Casein kinase I inhibitors for depleting stem cells
US10786547B2 (en)	2015-07-16	2020-09-29	Biokine Therapeutics Ltd.	Compositions, articles of manufacture and methods for treating cancer
ES2965461T3 (es)	2015-08-03	2024-04-15	Biokine Therapeutics Ltd	Inhibidor de CXCR4 para el tratamiento del cáncer
KR102033920B1 (ko)	2016-02-23	2019-10-18	바이오라인알엑스 리미티드	급성 골수성 백혈병을 치료하는 방법
US20210338767A1 (en)	2018-09-25	2021-11-04	Biolinerx Ltd.	Methods of selecting treatment for cxcr4-associated cancer
JP7542529B2 (ja)	2018-10-17	2024-08-30	バイオラインアールエックス・リミテッド	転移性膵臓腺癌の処置
JP7710045B2 (ja)	2020-12-30	2025-07-17	バイオラインアールエックス・リミテッド	ペプチドの製造プロセス
CA3205658A1 (en)	2020-12-30	2022-07-07	Efrat Halbfinger	Composition of bl-8040
WO2025224720A1 (en)	2024-04-24	2025-10-30	Biolinerx Ltd.	Methods of selecting treatment regimen against solid tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08504837A (ja)	1993-10-14	1996-05-28	生化学工業株式会社	新規ポリペプチドおよびこれから調製される抗ｈｉｖ剤
JP2002506830A (ja)	1998-03-13	2002-03-05	ザユニバーシティオブブリティッシュコロンビア	治療的ケモカイン受容体アンタゴニスト
AU2001236065A1 (en) *	2000-03-03	2001-09-12	Nobutaka Fujii	Antiviral compounds
AU2003261723A1 (en)	2002-08-27	2004-03-19	Takeda Chemical Industries, Ltd.	Cxcr4 antagonist and use thereof

2001
- 2001-09-05 DE DE60136373T patent/DE60136373D1/de not_active Expired - Lifetime
- 2001-09-05 CA CA2421183A patent/CA2421183C/en not_active Expired - Lifetime
- 2001-09-05 AU AU2001284419A patent/AU2001284419A1/en not_active Abandoned
- 2001-09-05 WO PCT/JP2001/007668 patent/WO2002020561A1/ja not_active Ceased
- 2001-09-05 US US10/363,209 patent/US7138488B2/en not_active Expired - Lifetime
- 2001-09-05 AT AT01963414T patent/ATE465170T1/de not_active IP Right Cessation
- 2001-09-05 JP JP2002525180A patent/JP4808363B2/ja not_active Expired - Fee Related
- 2001-09-05 EP EP01963414A patent/EP1323730B1/de not_active Expired - Lifetime
2006
- 2006-08-01 US US11/497,225 patent/US7595298B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20060264605A1 (en)	2006-11-23
JP4808363B2 (ja)	2011-11-02
CA2421183A1 (en)	2003-03-04
CA2421183C (en)	2015-06-16
EP1323730B1 (de)	2010-04-21
US7595298B2 (en)	2009-09-29
AU2001284419A1 (en)	2002-03-22
EP1323730A4 (de)	2005-01-05
JPWO2002020561A1 (ja)	2004-01-15
DE60136373D1 (de)	2008-12-11
EP1323730A1 (de)	2003-07-02
US20040116655A1 (en)	2004-06-17
US7138488B2 (en)	2006-11-21
WO2002020561A1 (en)	2002-03-14

Legal Events

Date	Code	Title	Description
2009-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties
2010-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60136373D1 (de)	2008-12-11	Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten
RU95112539A (ru)	1997-06-27	Новый полипептид и фармацевтическая композиция против вич-инфекции
DE3784799D1 (de)	1993-04-22	Malonsaeurederivate und ihre synthesemethoden.
WO2000012542A3 (en)	2000-06-29	Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
ES8802161A1 (es)	1988-04-01	Procedimiento para la obtencion de peptidos
DE69429176D1 (en)	2002-01-03	Protegrine
ATE213499T1 (de)	2002-03-15	Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
DE60144561D1 (de)	2011-06-16	N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide
WO2002048180A3 (de)	2003-01-30	Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels
ZA923213B (en)	1993-10-04	Polypeptides with affinity to lipopolysaccharides and their uses
ATE143024T1 (de)	1996-10-15	Aminoacyl und oligopeptidylderivate von allopurinol mit immunostimulierender wirkung und diese enthaltende pharmazeutische zubereitungen
WO2001027136A3 (fr)	2001-12-13	Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
ATE198987T1 (de)	2001-02-15	Behandlung von tropikalischer spastischer paresis mit peptide t
ATE3416T1 (de)	1983-06-15	Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
GR3020507T3 (en)	1996-10-31	New peptide derivatives, process to prepare them and their use as medicaments
AU2676399A (en)	1999-08-30	Novel cystine knot protein and materials and methods for making it
ATE46173T1 (de)	1989-09-15	Pharmakologisch aktive peptide.
ES416516A1 (es)	1976-03-01	Un procedimiento para la preparacion de nonapeptidos.
ATE178909T1 (de)	1999-04-15	Inhibitor peptid spezifisch für cathepsin-l
Schmidt et al.	1974	Primary Structure of Bovine Carboxypeptidase B: INFERENCES FROM THE LOCATIONS OF THE HALF-CYSTINES AND IDENTIFICATION OF THE ACTIVE SITE ARGININE
JPH0160003B2 (de)	1989-12-20
ATE207496T1 (de)	2001-11-15	Neue peptide und nootroper wirkstoff